House lawmakers are expected to vote next week on the Marijuana Opportunity, Reinvestment and Expungement, or MORE Act that would remove marijuana from the list of federally controlled substances.

“The MORE Act could be a game changer for USMJ, PURA and PJET,” said Steven Rash, Chairman of ACI Conglomerated and the CEO of USMJ. “Investment and financing of all three companies is complicated by the current federal prohibition of cannabis.  Legalization would open all three companies to new resources that could drive exponential growth.”

USMJ is a cannabis e-commerce company marketing their own, and third-party cannabis-related products. PURA is industrial hemp sector co-op.  PJET is a former cannabis sector company recently shifting into the student life sector but impacted by both its cannabis history and relationship with USMJ and PURA.

Disclaimer:
This News Release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. These forward-looking statements involve known and unknown risks, uncertainties and other important factors that could cause our actual results, performance or achievements, or industry results, to differ materially from any these statements. You are cautioned not to place undue reliance on any those forward-looking statements. Except as otherwise required by the federal securities laws, we undertake no obligation to publicly update or revise any forward-looking statements after the date of this news release. None of such forward-looking statements should be regarded as a representation by us or any other person that the objectives and plans set forth in this News Release will be achieved or be executed.

Contact:
ACI Conglomerated
Steven Rash
info@aciconglomerated.com
+1 (800) 861-1350

This is a press release. Click here to see the original story.

Featured image: “marihuana” by Amnesi-a is marked with CC BY-ND 2.0.

The post ACI Optimistic for Growth Potential of USMJ, PURA and PJET from Federal Marijuana Legalization appeared first on Investor News.

The corporate identified for numerous merchandise with cannabinoid and different pure elements launched the non-public placement by way of the DealSquare platform, which is supported by NEO and DealMaker expertise.

DealSquare is an automatic platform that permits capital raisers to launch their non-public placement gives, and buyers to electronically enter a deal. NEO is a bunch of fintech firms that supply capital markets infrastructure, and DealMaker grants the back-office expertise and digital signature providers.

This capital increase is the primary one by way of mixed service choices of DealMaker and DealSquare. MedC Biopharma has created two medication going through medical trials concentrating on Pores and skin T-cell Lymphoma and Cutaneous Leishmaniasis, each of that are thought-about orphan circumstances.

“The launch of our private offering leveraging the joint service capabilities of those respected platforms marks a big step in direction of MedC taking its place amongst trade leaders which are decided to legitimize and ship the well being advantages of cannabinoids to the worldwide neighborhood,” said Dr. Owen Van Cauwenberghe, President of MedC.

“Our tireless efforts and dedication to substantiated medical and well being claims for these merchandise will be certain that their advantages shall be out there to all these in want. We’re lucky to have the ability to make the most of the mixed DealSquare, NEO, and DealMaker providing.”

The corporate famous it plans to make use of the raised capital to help its worldwide growth, first throughout Australia and Canada, and later to achieve Europe, UK, Latin America, and Asia.

Moreover, MedC Biopharma may also broaden its portfolio of merchandise.

The post MedC Biopharma Corporation Launches $3M Private Placement Offering appeared first on Investor News.